RAPP · XBRL financial data
Rapport Therapeutics financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (RAPP's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Research and development | 60,935 | 94,789 |
| General and administrative | 22,120 | 30,310 |
| Total operating expenses | 83,055 | 125,099 |
| Operating income (loss) | (83,055) | (125,099) |
| Interest income | 12,138 | 13,616 |
| Income tax expense (benefit) | 0 | 0 |
| Net income (loss) | (78,307) | (111,483) |
| Earnings per share, basic USD per share | (3.78) | (2.86) |
| Earnings per share, diluted USD per share | (3.78) | (2.86) |
| Weighted average shares, basic thousands of shares | 20,738 | 38,935 |
| Weighted average shares, diluted thousands of shares | 20,738 | 38,935 |
Balance sheet
CSVFiscal years (RAPP's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Cash and cash equivalents | 56,805 | 52,645 |
| Short-term investments | 248,475 | 437,894 |
| Accounts receivable | — | 0 |
| Prepaid and other current assets | 4,417 | 7,917 |
| Total current assets | 309,802 | 498,561 |
| Property and equipment, net | 3,529 | 2,976 |
| Right-of-use asset | 1,442 | 9,909 |
| Total assets | 314,933 | 512,431 |
| Accounts payable | 1,954 | 4,190 |
| Accrued liabilities | 6,076 | 12,104 |
| Total current liabilities | 8,767 | 19,049 |
| Lease liability, non-current | 739 | 8,729 |
| Total liabilities | 9,506 | 27,778 |
| Accumulated deficit | (123,745) | (235,228) |
| Total stockholders' equity | 305,427 | 484,653 |
| Total liabilities and equity | 314,933 | 512,431 |
| Common shares outstanding (cover page) thousands of shares | 36,496 | 47,793 |
Cash flows
CSVFiscal years (RAPP's year ends in late December)
| In thousands of dollars | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Net income (loss) | (78,307) | (111,483) |
| Stock-based compensation | 10,235 | 18,855 |
| Depreciation and amortization | 839 | 1,017 |
| Net cash from operating activities | (64,828) | (87,473) |
| Purchases of property and equipment | 2,405 | 616 |
| Net cash from investing activities | (170,141) | (187,473) |
| Net cash from financing activities | 221,625 | 270,786 |
| Net change in cash | (13,344) | (4,160) |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Rapport Therapeutics | 74,754 | 0 | (41,633)* | 59.3M | 12.3 quarters | 10-QSep 30, 2026 |
| Abeona Therapeutics | 56,229 | 11,380 | (17,496)* | 57.2M | 8.4 quarters | 10-QJun 30, 2026 |
| Ocugen | 24,632 | 1,951 | (15,739)* | 339.3M | 5.1 quarters | 10-QSep 30, 2026 |
| Tonix Pharmaceuticals Holding | 176,232 | 13,544 | (42,243)* | 17.2M | 4.2 quarters | 10-QJun 30, 2026 |
| Vanda Pharmaceuticals | 61,933 | 69,815 | (28,435)* | 60.5M | 1.7 quarters | 10-QSep 30, 2026 |
| Atea Pharmaceuticals | 76,548 | not reported | (37,084)* | 80.2M | 5.9 quarters | 10-QJun 30, 2026 |
| Standard Biotools | 267,487 | 19,385 | (6,161)* | 394.8M | 21.6 quarters | 10-QSep 30, 2026 |
| Aquestive Therapeutics | 90,349 | 7,557 | (7,046)* | 125.7M | 8.4 quarters | 10-QSep 30, 2026 |
| Verastem | 136,353 | 40,078 | (43,909)* | 90.6M | 3.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.